Cellectar Biosciences, Inc.
Key Metrics
Market Snapshot
About
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer treatment. Headquartered in Florham Park, New Jersey, the company's proprietary phospholipid ether (PLE) platform selectively delivers radiation to cancer cells and the tumor microenvironment. Cellectar's lead product candidate, iopofosine I 131, is being evaluated for relapsed/refractory multiple myeloma and other hematologic malignancies. The PLE platform's tumor-targeting mechanism offers potential advantages over conventional radiotherapy by concentrating therapeutic radiation while sparing healthy tissue.